September 19, 2018 NIAID Funding News

Read this full issue online at http://www.niaid.nih.gov/grants-contracts/funding-news-notices

Feature Articles

Comment on Draft Updates to NIH's Clinical Trial Protocol Template

The Behavioral and Social Sciences Clinical Trials Template will inform an update to the Clinical e-Protocol Writing Tool, which applicants can use as a guide when preparing comprehensive clinical protocols for Phase 2 and 3 clinical trials.

Opportunities and Resources

Take Requisite Steps Now for Clinical Center FOA

To apply for the Expanding Extramural Research Opportunities at the NIH Clinical Center funding opportunity announcement, you'll first need to obtain a letter from the Clinical Center director to confirm that the Clinical Center facilities will be able to accommodate your proposed research.

New Way To Apply for Academic Research Enhancement Award

NIAID will support Academic Research Enhancement Awards focused on undergraduate institutions or academic components in which the undergraduate student enrollment is greater than the graduate student enrollment.

Reissued Opportunity for Supplements: Improve Research Workforce Diversity

NIAID will help current grantees recruit and support students, postdocs, and other eligible investigators from diverse backgrounds to work on research experiences integral to a grant's ongoing research, with the potential to contribute significantly to the career development of the candidates.

In The News

Stay Abreast of Important NIH and NIAID Resources

Check out a list of five new resources, which includes helpful information on informed consent, intellectual property security, and early-stage investigator status, to ensure you're following the latest guidance on these topics.

Comment on Proposed Changes to Human Gene Therapy Trials

Proposed changes to the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules would 1) remove the NIH protocol submission, review, and reporting requirements under Appendix M of the NIH Guidelines and 2) modify the roles and responsibilities of the Recombinant DNA Advisory Committee.